Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.78 |
| ▸ | APAF1 | O14727 | 8/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.78 |
| ▸ | GAA | P10253 | 5/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | HTT | P42858 | 3/20 | 0.78 |
| ▸ | MITF | O75030 | 6/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16297097 | 0.90 | MAPT (0.81) | MEN1KMT2ANSD2MAPTAPAF1 | |
| SCHEMBL16297025 | 0.88 | MEN1 (0.78) | MEN1KMT2ANSD2MAPTAPAF1 | |
| SCHEMBL16296852 | 0.88 | MEN1 (0.78) | MEN1KMT2ANSD2MAPTAPAF1 | |
| SCHEMBL16296824 | 0.88 | MEN1 (0.78) | MEN1KMT2ANSD2MAPTAPAF1 | |
| SCHEMBL16296653 | 0.88 | APAF1 (0.82) | MEN1KMT2ANSD2MAPTAPAF1 | |
| SCHEMBL16296848 | 0.82 | APAF1 (0.79) | MEN1KMT2ANSD2MAPTAPAF1 | |
| SCHEMBL16297080 | 0.80 | MEN1 (0.66) | MEN1KMT2ANSD2MAPTAPAF1 | |
| SCHEMBL16297049 | 0.78 | MAPT (0.80) | MEN1KMT2ANSD2MAPTAPAF1 | |
| SCHEMBL16296991 | 0.77 | APAF1 (1.00) | MEN1KMT2ANSD2MAPTAPAF1 | |
| SCHEMBL16296794 | 0.77 | APAF1 (0.73) | MEN1KMT2ANSD2MAPTAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745261-B2 | Inhibitors of the MITF molecular pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE BROAD INSTITUTE, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-3007688-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | The General Hospital Corporation (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014201016-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014201016-A2 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130222-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | MEN1 1616/4885KMT2A 2018/4885NSD2 1800/4885 |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | MEN1 1568/4885KMT2A 2146/4885NSD2 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.